Dose escalation results of ceritinib and nivolumab for ALK NSCLC
Dose escalation results of ceritinib and nivolumab for ALK NSCLC
Phase III results of olaparib for BRCA breast cancer
Global health initiative oncology
Self-reporting symptoms online improves patient care, chemotherapy duration and survival
Tivantinib as second line therapy for high-MET HCC
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy
Web-based system for self-reporting symptoms may help patients live longer
Olaparib slows growth of BRCA-related metastatic breast cancer
Global study sets new risk-based standard to personalise chemotherapy for colon cancer after surgery
3 or 6 months adjuvant oxaliplatin for colorectal cancer
No link between pregnancy and breast cancer relapse
Cancer and caring in modern medicine